THERAPY DOSSIER · th-14a078376f0c

Necrostatin-1 with anti-HMGB1 neutralising antibody or HMGB1 inhibition

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31961020 ↗2020Reported benefit

HMGB1-associated necroptosis and Kupffer cells M1 polarization underlies remote liver injury induced by intestinal ischemia/reperfusion in rats.

RatIschaemia-reperfusionIntestinal / mesentericSprague-DawleyMale

Model: Intestinal ischaemia/reperfusion with 6 hours of reperfusion, causing remote acute liver injury

Intestinal ischaemia/reperfusion caused hepatocyte necroptosis and remote liver dysfunction. Necrostatin-1 and HMGB1 neutralisation or inhibition reduced HMGB1 cytoplasmic translocation, hepatocyte necroptosis, tissue inflammation and M1 polarisation of Kupffer cells and circulating macrophages, pa…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…